Tsai, Her Hsin <br/><br/>
A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.  [electronic resource] 

 -  Expert review of pharmacoeconomics & outcomes research  Dec 2016 
 - 679-683 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-8379 
<br/><br/><label>Standard No.: </label>10.1080/14737167.2016.1246186  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--economics<br/>Colitis, Ulcerative--drug therapy<br/>Cost-Benefit Analysis<br/>Gastrointestinal Agents--economics<br/>Humans<br/>Integrins--antagonists & inhibitors<br/>Severity of Illness Index<br/>United Kingdom